• Revenue down 10% to $2.64 million
• Operating profit after tax of $127k, turnaround from $464k loss
• Gross profit margin improved by 280 bps, operating expenses reduced by 44%

Anagenics Ltd has released its Appendix 4D for the half-year ended 31 December 2025. Revenue and other income from ordinary activities was down 10% to $2,635,660 compared to the prior corresponding period. However, the company reported a significant turnaround in profitability, with operating profit after tax of $126,685, compared to a loss of $463,929 in the prior corresponding period. This improvement was driven by a 280 basis point increase in gross profit margin and a 44% reduction in operating expenses, following the company's recent restructuring. There were no dividends paid, recommended or declared during the half-year. Net tangible assets per ordinary share improved from a deficit of 3 cents per share at 30 June 2025 to an asset position of 6 cents per share at 31 December 2025.